A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.

IF 3.3 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE
Zemene Demelash Kifle, Engidaw Fentahun Enyew, Abebe Basazn Mekuria
{"title":"A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.","authors":"Zemene Demelash Kifle,&nbsp;Engidaw Fentahun Enyew,&nbsp;Abebe Basazn Mekuria","doi":"10.1177/2515690X211003727","DOIUrl":null,"url":null,"abstract":"<p><p>Currently, the coronavirus disease 2019 (COVID-19) is a big challenge to the healthcare systems in the world. Several researchers in the world have immediately carried out clinical investigations for the discovery of vaccines and drugs. Different studies have shown that antiviral measures including small bioactive compounds targeting multifaceted molecular communications take in COVID-19 infection. The drug development archived in this review emphasizes mainly on drugs that are effective for the Management of MERS-CoV, SARS-CoV, and other RNA viruses. The investigation of therapeutic agents for COVID-19 includes anti-inflammatory agents, antibodies, and nucleic acid-based treatments targeting virus gene expression as well as different sorts of vaccines. Numerous patents revealed techniques of these biologics with the potential for treating and preventing coronavirus infections, which may apply to COVID-19. Phase 3 clinical trials such as Sputnik V, AZD1222, mRNA-1273, BNT162b2, Ad5-nCoV, Anti-COVID antibodies, Kevzara; Actemra, Jakafi; Baricitinib, and some others were undergoing in the race for Covid-19 treatment. However, there's still a lack of a review on vaccines and drugs for COVID-19 management. Therefore, this review summarizes different studies that are ongoing in the race for Covid-19 protection and treatment.</p>","PeriodicalId":15714,"journal":{"name":"Journal of Evidence-based Integrative Medicine","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2515690X211003727","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Evidence-based Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2515690X211003727","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 2

Abstract

Currently, the coronavirus disease 2019 (COVID-19) is a big challenge to the healthcare systems in the world. Several researchers in the world have immediately carried out clinical investigations for the discovery of vaccines and drugs. Different studies have shown that antiviral measures including small bioactive compounds targeting multifaceted molecular communications take in COVID-19 infection. The drug development archived in this review emphasizes mainly on drugs that are effective for the Management of MERS-CoV, SARS-CoV, and other RNA viruses. The investigation of therapeutic agents for COVID-19 includes anti-inflammatory agents, antibodies, and nucleic acid-based treatments targeting virus gene expression as well as different sorts of vaccines. Numerous patents revealed techniques of these biologics with the potential for treating and preventing coronavirus infections, which may apply to COVID-19. Phase 3 clinical trials such as Sputnik V, AZD1222, mRNA-1273, BNT162b2, Ad5-nCoV, Anti-COVID antibodies, Kevzara; Actemra, Jakafi; Baricitinib, and some others were undergoing in the race for Covid-19 treatment. However, there's still a lack of a review on vaccines and drugs for COVID-19 management. Therefore, this review summarizes different studies that are ongoing in the race for Covid-19 protection and treatment.

Abstract Image

Abstract Image

在COVID-19保护和治疗竞赛中发现和开发疫苗和治疗剂的最新成就。
目前,2019冠状病毒病(COVID-19)对世界卫生系统构成了巨大挑战。世界上有几位研究人员立即开展了临床研究,以发现疫苗和药物。不同的研究表明,包括靶向多面分子通信的小生物活性化合物在内的抗病毒措施在COVID-19感染中起作用。本文综述的药物开发主要集中在MERS-CoV、SARS-CoV和其他RNA病毒的有效治疗药物。新冠肺炎治疗剂的研究包括抗炎药、抗体、针对病毒基因表达的核酸治疗以及不同类型的疫苗。许多专利揭示了这些生物制剂的技术,这些技术具有治疗和预防冠状病毒感染的潜力,可能适用于COVID-19。Sputnik V、AZD1222、mRNA-1273、BNT162b2、Ad5-nCoV、Anti-COVID抗体、Kevzara等三期临床试验;Actemra Jakafi;巴西替尼和其他一些药物正在接受Covid-19治疗。然而,目前仍缺乏对COVID-19管理疫苗和药物的审查。因此,本综述总结了在Covid-19保护和治疗竞赛中正在进行的不同研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Evidence-based Integrative Medicine
Journal of Evidence-based Integrative Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-
CiteScore
5.90
自引率
0.00%
发文量
43
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信